antiviral activity

Related by string. Antiviral Activity * anti viral . anti virals . antivirals . Antiviral . Antivirals : antiviral medications . stockpiling antiviral drugs . antiviral medication . antiviral drugs Tamiflu . potent antiviral / ACTIVITY . activ ity . Activity : contracting activity N# . DETECTS UNUSUAL ACTIVITY IN . Detects Unusual Activity . Physical Activity * Potent Antiviral Activity *

Related by context. All words. (Click for frequent words.) 75 antitumor activity 75 antiviral efficacy 72 antiviral potency 71 tolerability profile 71 oral bioavailability 70 pharmacokinetic profile 69 tolerability 69 potent antiviral 68 immunogenicity 67 favorable pharmacokinetic profile 67 pharmacodynamic profile 67 anti leukemic 67 cytotoxicity 66 vivo efficacy 66 viral kinetics 66 radezolid 66 nitazoxanide 66 efficacy 66 viral suppression 66 antibody responses 66 S/GSK# 66 INGN 65 bactericidal activity 65 pharmacokinetic properties 65 Thiovir 65 safety tolerability pharmacokinetic 65 anticancer activity 64 systemic absorption 64 BAL# [001] 64 Preclinical studies 64 pharmacokinetics PK 64 bortezomib 64 pharmacokinetics 64 solithromycin 64 bevirimat 64 CYT# 64 pharmacodynamic properties 64 immunomodulator 64 SCH # 64 pharmacodynamic 64 pomalidomide 64 orally bioavailable 64 polymerase inhibitor 63 HGS ETR1 63 oral prodrug 63 Carfilzomib 63 preclinically 63 RDEA# 63 GLYX 63 virologic response 63 antibody titers 63 delafloxacin 63 xenograft models 63 posaconazole 63 milatuzumab 63 tipranavir 63 nucleotide analog 63 IDX# 63 antitumor efficacy 63 ganetespib 63 ENMD # 63 antitumor effects 63 NEUGENE 63 potent antitumor activity 63 vitro potency 63 Interferon alpha 62 highly immunogenic 62 retapamulin 62 HCV genotypes 62 vitro studies 62 TRIOLEX 62 PXD# 62 ritonavir boosted 62 antitumor 62 elvitegravir 62 decitabine 62 virologic 62 potent inhibition 62 Sym# 62 pharmacokinetic 62 immune responses 62 Traficet EN 62 nanomolar 62 IFN alpha 62 preclinical efficacy 62 PEG Interferon lambda 62 HCV protease 62 teriflunomide 62 NXL# 62 XmAb# 62 neuroprotective properties 61 Imprime PGG 61 mapatumumab 61 tolerability profiles 61 favorable tolerability 61 preclinical studies 61 pharmacokinetic profiles 61 HCV 61 OXi# 61 antitumor effect 61 immunological responses 61 viral load 61 oral FTY# 61 immunomodulatory 61 Multimeric 61 PRTX 61 dosing regimens 61 INCB# [001] 61 HCV replicon 61 AEZS 61 seliciclib 61 thymalfasin 61 oral antiviral 61 Vidofludimus 61 systemically administered 61 TMC# [001] 61 integrase inhibitor 61 NS4A 61 neutralizing antibody 61 Valortim ® 60 CCR5 antagonist 60 ascending doses 60 OncoVEX GM CSF 60 nanoviricides 60 pharmacodynamics 60 pan HDAC inhibitor 60 administered subcutaneously 60 Valortim R 60 ON #.Na 60 antimicrobial efficacy 60 Pharmacokinetics PK 60 VAX# 60 viral kinetic 60 PI3K inhibitor 60 immunogenic 60 VLP vaccine 60 PS# [001] 60 neurotoxicity 60 rFIXFc 60 PMX # 60 GFT# 60 seroconversion 60 HGS ETR2 60 peripheral blood mononuclear 60 Antiviral Activity 60 lopinavir 60 monotherapy 60 protease inhibitor PI 60 pharmacodynamic effects 60 TG# [003] 60 tumor regression 60 dose limiting toxicities 60 riociguat 60 CBLC# 60 axitinib 60 NS#/#A protease 60 obatoclax 60 BAL# [002] 60 Serdaxin 60 telbivudine 60 #ME# 59 bendamustine 59 CIMZIA TM 59 antiangiogenic activity 59 inhibitory activity 59 NRTI 59 pharmacodynamic PD 59 neuraminidase inhibitor 59 mTOR inhibitors 59 Symadex 59 torezolid 59 IMGN# 59 Pegasys ® 59 dose cohorts 59 APOPTONE 59 seroprotection 59 telaprevir VX 59 raltegravir 59 pegylated 59 cidofovir 59 Phase 2a trial 59 selective inhibitor 59 CCX# 59 protease inhibitor 59 PRT# 59 DermaVir Patch 59 selective orally bioavailable 59 bioactivity 59 hemagglutination inhibition HAI 59 MGCD# [002] 59 Tarvacin 59 IFN α 59 pharmacokinetic interactions 59 mcg dose 59 pharmacokinetic studies 59 HQK 59 liposomal formulation 59 analgesic efficacy 59 NNRTIs 59 Valortim 59 HIV RNA 59 sustained virologic response 59 amprenavir 59 oritavancin 59 RGB # 59 polymerase inhibitors 59 low dose ritonavir 59 immunomodulatory effects 59 Bezielle 59 elvucitabine 59 ANA# 59 Phase 1b 59 CYC# 59 JVRS 59 vidofludimus 58 pegylated interferon alfa 2a 58 nanoviricide 58 AEG# 58 BioVant 58 HGS# 58 influenza VLP vaccine 58 vascular disrupting agent 58 Azixa 58 pegylated interferon 58 investigational protease inhibitor 58 DAS# [001] 58 tanespimycin 58 cytoprotective 58 PEG SN# 58 peginterferon alfa 2b 58 immunostimulatory 58 forodesine 58 Cethromycin 58 daunorubicin 58 sapacitabine 58 Debio 58 transgene expression 58 INT# [002] 58 anti EGFR antibody 58 inhibitory effects 58 pharmacodynamics PD 58 talabostat 58 active comparator 58 inhibitor RG# 58 immunomodulating 58 CG# [003] 58 DXL# 58 vitro cytotoxicity 58 pharmacokinetic parameters 58 EpCAM 58 interferon IFN 58 pharmacokinetic PK 58 dose escalation trial 58 boosted protease inhibitor 58 NEUGENE antisense 58 nab paclitaxel 58 celgosivir 58 nucleoside 58 GRN#L 58 Azedra 58 ceftaroline 58 fosbretabulin 58 alpha 2a 58 APTIVUS 58 dose proportionality 58 caspofungin 58 nucleoside reverse transcriptase inhibitor 58 HCV replication 58 fosamprenavir 58 nelfinavir 58 Tolerability 58 Blinatumomab 58 safety tolerability 58 dasatinib 58 Phase 1b trial 58 Perifosine 58 nanoviricide drug 58 #th Annual Interscience 58 Hsp# inhibitors 58 eltrombopag 58 davunetide intranasal AL 58 CLORETAZINE TM VNP#M 58 Apoptone 58 orally dosed 58 vicriviroc 58 nanomolar potency 58 tolerated dose MTD 58 selective modulator 58 CTAP# Capsules 58 nucleoside analogues 58 perifosine 58 virological response 58 DAVANAT 58 macrolides 58 renal toxicity 58 erlotinib Tarceva ® 58 inecalcitol 58 adefovir 58 antiviral 58 tigecycline 58 anti proliferative 58 bactericidal 58 nonclinical studies 58 dose regimens 58 LEXIVA r 58 demonstrated antitumor activity 58 pharmacokinetic PK profile 58 plasma concentrations 58 oral JAK1 58 pegylated liposomal doxorubicin 58 depsipeptide 57 tumor xenograft models 57 darunavir 57 neutralizing antibodies 57 murine 57 trastuzumab Herceptin R 57 IRX 2 57 GM CSF 57 SRT# [003] 57 nucleoside analog 57 HCV genotype 1 57 darunavir Prezista 57 CANCIDAS 57 replicon 57 chlorambucil 57 NNRTI resistance 57 HspE7 57 virologic responses 57 H#N# VLP vaccine 57 interferon alpha 57 imatinib Gleevec ® 57 pharmacokinetic characteristics 57 attenuated strain 57 MenACWY CRM 57 trodusquemine 57 ITMN 57 phase Ib 57 K ras mutations 57 HDAC inhibitor 57 protein kinase inhibitor 57 nephrotoxicity 57 BMS # 57 PSN# [002] 57 amrubicin 57 rHuPH# 57 safety tolerability pharmacokinetics 57 rapid virologic response 57 DepoVax 57 R#/MEM # 57 peg IFN 57 REYATAZ r 57 adecatumumab 57 alfa 2a 57 bioavailability 57 RoACTEMRA 57 OMP #M# 57 Hematologic toxicity 57 genotypic 57 potent inhibitor 57 biodistribution 57 log# reduction 57 targeting CD# 57 anticancer 57 plus ribavirin 57 virus HCV protease inhibitor 57 selective agonist 57 meropenem 57 IMA# 57 erlotinib 57 CRx 57 neutralizing antibody responses 57 ProLindac 57 nucleoside naive patients 57 interferon 57 HCV RNA 57 MEK inhibitors 57 torezolid phosphate 57 Darinaparsin 57 AEGR 57 recurrent genital herpes 57 BRAF inhibitor 57 entecavir 57 ciclesonide 57 DB# [003] 57 itraconazole 57 HuLuc# 57 Tarvacin TM 57 lopinavir r 57 sunitinib Sutent ® 57 reactogenicity 57 iSONEP 57 OHR/AVR# 57 Telbivudine 57 Triolex 57 alvespimycin 57 bronchodilation 57 PREZISTA r 57 APTIVUS r 57 CA4P 57 bavituximab 57 trabectedin 57 anti amnesic 57 peginterferon alfa 2a 57 paclitaxel Taxol 57 hour bronchodilation 57 JAK inhibitor 57 apremilast 57 VZV 57 dose proportional pharmacokinetics 57 immune modulating 57 abacavir lamivudine 57 NRTIs 57 HCV infected 57 interferon alfa 57 Tyrima 57 HCV genotype 57 evaluating tivozanib 57 CCR2 57 tolerability pharmacokinetics 57 lamivudine 57 ORMD 57 HuMax EGFr 57 Elacytarabine 57 ABC/3TC 57 CCR9 57 REP# 57 ISIS # 57 induce apoptosis 57 Phase Ib clinical 57 CD8 responses 57 elotuzumab 57 VIR# 57 cilengitide 57 T#I mutant 57 cytotoxic 57 enzastaurin 57 rNAPc2 57 cMET 57 velafermin 57 tocilizumab 57 peptide antigens 57 mg kg dose 57 CGEN # 57 daptomycin 57 CDK inhibitor 57 dose ritonavir 57 randomized Phase III 57 dosage regimens 57 enfuvirtide 56 vivo potency 56 pegylated interferon alpha 56 #mg dose [001] 56 pro apoptotic 56 maximally tolerated dose 56 hematological cancers 56 FluCide 56 binding affinity 56 TLR7 56 plasma pharmacokinetics 56 pertuzumab 56 inhibitory effect 56 INCB# [002] 56 ISENTRESS 56 Tarceva TM 56 ARRY 56 generation Hsp# inhibitors 56 Archexin 56 Phase 2a 56 nucleotide analogs 56 subcutaneous formulation 56 Ostarine 56 pharmacokinetic equivalence 56 immune stimulatory 56 docetaxel chemotherapy 56 imetelstat 56 FOLFIRI 56 anti angiogenic 56 investigational oral 56 NGX# 56 immune reconstitution 56 Pharmacokinetic studies 56 novel histone deacetylase 56 imatinib therapy 56 antitumour activity 56 ZYBRESTAT 56 HDAC 56 vitro experiments 56 tipifarnib 56 ceftazidime 56 eculizumab 56 IMC A# 56 fluconazole 56 stated Michelle Berrey 56 iniparib 56 novel VDA molecule 56 subcutaneously administered 56 calcitriol 56 FTY# fingolimod 56 Belerofon 56 Phase Ib study 56 busulfan 56 pharmacokinetic PK study 56 BARACLUDE ® 56 VEGF receptors 56 Phase #/#a 56 non nucleoside 56 linear pharmacokinetics 56 viremia 56 XL# [003] 56 Protelos 56 docetaxel 56 vivo 56 Altastaph 56 CIMZIA ™ 56 sorafenib Nexavar 56 Radezolid 56 selective kinase inhibitor 56 histone deacetylase HDAC inhibitor 56 CR# vcMMAE 56 titers 56 calcitonin 56 Zoraxel 56 TCAD therapy 56 huN# DM1 56 mycophenolate mofetil 56 VLPs 56 ascending dose 56 Elvitegravir 56 limiting toxicity 56 relapsed MM 56 sunitinib 56 Omacetaxine mepesuccinate 56 TMC# r 56 Phase 1b clinical 56 melphalan prednisone 56 rhIL 7 56 plasma kallikrein inhibitor 56 Preclinical studies suggest 56 fulvestrant 56 LY# [003] 56 GMX# 56 rituximab 56 indibulin 56 antiapoptotic 56 efficacy tolerability 56 gemcitabine Gemzar 56 AAV2 56 cyclophilin inhibitor 56 echinocandins 56 IL #E 56 AP# [003] 56 flavopiridol 56 nucleoside analogue 56 NRTI resistance 56 dexamethasone Decadron 56 genotypic resistance 56 Xanafide 56 IMP# 56 elacytarabine 56 mg BID 56 ribavirin RBV 56 HDAC inhibitors 56 #mg BID [003] 56 neuroprotective effects 56 overlapping toxicities 56 TRV# [001] 56 FOLFOX chemotherapy 56 humanized anti 56 mg dose 56 toxicities 56 chronic HCV infection 56 Tezampanel 56 Menerba 56 TriRima 56 Dasatinib 56 sorafenib 56 azoles 56 G CSF 56 cariprazine 56 Vitro Activity 56 azacytidine 56 dosing schedules 56 pharmacokinetics pharmacodynamics 56 combinability 56 MGCD# [001] 56 Hepatitis C virus HCV 56 azacitidine 56 monovalent 56 administered orally 56 cobicistat 56 preclinical models 56 temsirolimus 56 Pharmacokinetic 56 fluoroquinolone antibiotic 56 SIV infection 56 Tindamax R 56 CD# monoclonal antibody 56 cytarabine 56 rilpivirine 56 Interferon alfa 56 VEGFR2 56 HDACi 56 small molecule defensin 56 multi kinase inhibitor 56 μg dose 56 transfected 56 leukemia AML 55 Anthim 55 BiovaxID 55 lintuzumab 55 secondary efficacy endpoints 55 antidepressant efficacy 55 dose regimen 55 Actilon 55 otelixizumab 55 ara C 55 Seliciclib 55 LPV r 55 small molecule inhibitor 55 tiotropium 55 Phase IIa trial 55 Amigal 55 IgG antibodies 55 ATL/TV# 55 voreloxin 55 valopicitabine 55 selective inhibition 55 pharmacodynamic profiles 55 generation NNRTI 55 dose escalation study 55 CORT # 55 GRNVAC1 55 fusidic acid 55 maraviroc 55 orally administered inhibitor 55 amphotericin B 55 Kinoid 55 pharmacokinetic pharmacodynamic 55 prucalopride 55 tyrosine kinase inhibitor 55 ADAGIO study 55 Aptivus ® 55 HCV protease inhibitors 55 #mg ritonavir 55 recombinant protein 55 live attenuated influenza 55 PROCHYMAL 55 Aurora kinase 55 siRNA mediated 55 darunavir r 55 virologic failure 55 HBeAg positive 55 baminercept 55 Pegasys R 55 GAP #B# 55 samalizumab 55 carboplatin paclitaxel 55 PCK# 55 monoclonal antibody MAb 55 beta lactam antibiotic 55 biologic DMARD 55 dose cohort 55 Afatinib 55 MLN# 55 chemotherapeutic drug 55 Reverset 55 proteasome inhibitors 55 CRLX# 55 histone deacetylase inhibitor 55 HIF PHI 55 Panzem R NCD 55 mCRC patients 55 E. faecalis 55 chemopreventive 55 IgG1 55 TG# [001] 55 FasL 55 Omacetaxine 55 VP# [004] 55 hA# 55 antitumor responses 55 KRAS status 55 TMC# [002] 55 INTELENCE 55 pyrazinamide 55 bexarotene 55 Vaxfectin 55 dosed orally 55 LT NS# 55 antithrombotic 55 heavily pretreated 55 tumor regressions 55 Peginterferon 55 anticancer agent 55 refractory gout 55 HCV protease inhibitor 55 varespladib 55 dexpramipexole 55 Bevirimat 55 kinase inhibitor 55 HuMax CD# 55 Gag polymorphisms 55 forskolin 55 TRO# 55 Copegus ribavirin 55 HCV SPRINT 55 Onconase 55 sustained virological response 55 effector function 55 adalimumab 55 viral replication 55 Amplimexon 55 elesclomol 55 Pegasys plus Copegus 55 SARS CoV 55 metaglidasen 55 Targretin 55 investigational compound 55 gemcitabine carboplatin 55 CEQ# 55 oral rivaroxaban 55 huC# DM4 55 vaccine TIV 55 aclidinium 55 VELCADE melphalan 55 ACTEMRA TM 55 sulodexide 55 indinavir 55 entinostat 55 AzaSite Plus 55 ACTEMRA 55 pandemic influenza strains 55 low dose cytarabine 55 Epothilones 55 selective antagonist 55 Phase Ib II 55 INC# 55 Hsp# inhibitor 55 phase IIb clinical 55 alkylating agent 55 glucose lowering 55 Taxotere ® 55 pharmacodynamic markers 55 FTY# 55 OncoVEX 55 factor G CSF 55 lamivudine 3TC 55 dacetuzumab 55 pathophysiological effects 55 neratinib 55 Phase Ib 55 viral titers 55 bosentan 55 insulin degludec 55 Phase IIa clinical 55 fluticasone furoate 55 antisense compounds 55 abatacept 55 Enzastaurin 55 Bendavia 55 single ascending dose 55 atazanavir ritonavir 55 Erlotinib 55 lopinavir ritonavir Kaletra 55 micafungin 55 MET amplification 55 doripenem 55 telaprevir dosed 55 Immunogenicity 55 atazanavir Reyataz 55 corticosteroid dexamethasone 55 IFN gamma 55 afatinib 55 REMUNE R 55 Protease Inhibitor 55 AAG geldanamycin analog 55 gemcitabine 55 PEGylated interferon beta 1a 55 darunavir ritonavir 55 ALN RSV# 55 Viramidine 55 Alpharadin 55 investigational humanized monoclonal antibody 55 mg/m2 dose 55 plus gemcitabine 55 serum antibody 55 romidepsin 55 Cotara 55 DermaVir 55 paricalcitol 55 BRAF mutation 55 Phase 2b study 55 delta isoform 55 docetaxel Taxotere 55 tenofovir Viread 55 erythropoietic 55 atazanavir 55 cardioprotective effects 55 XP# Transported Prodrug 55 EGFr 55 Vfend 55 Gleevec resistant 55 receptor inhibitor 55 humanized monoclonal antibody 55 MAGE A3 ASCI 55 pramlintide metreleptin combination 55 HuMax CD4 55 reversible inhibitor 55 Locteron 55 lenalidomide Revlimid R 55 chlamydial 55 glufosfamide 55 cethromycin 55 Vacc 4x 55 INVIRASE 55 steroid dexamethasone 55 teduglutide 55 PEG IFN 55 bicifadine 55 Ribavirin 55 leucovorin 55 octreotide acetate 55 ongoing Phase 1b 55 CaPre TM 55 kinase inhibition 55 GHRH 55 cetuximab 55 vascular disrupting 55 virologic suppression 55 PD LID 55 FOLFOX 55 Peg IFN 55 oral ridaforolimus 55 Maribavir 55 edoxaban 55 complete cytogenetic response 55 HCV infection 55 cytotoxic T 55 dasatinib Sprycel ® 55 bevacizumab 54 TREANDA 54 quinolone 54 ALV# 54 RG# ITMN 54 pegylated interferon alfa 54 interferon alfa 2b 54 AZT zidovudine Retrovir 54 ertapenem 54 retaspimycin 54 Eg5 54 piperacillin tazobactam 54 bortezomib Velcade ® 54 receptor tyrosine kinase inhibitor 54 hepatoma 54 TMC# C# 54 CXB# 54 mertansine 54 somatostatin 54 pegylated interferons 54 Irinotecan 54 iclaprim 54 ciclosporin 54 CD# antibodies 54 YONDELIS 54 LC#m# 54 bronchodilatory 54 mGluR5 NAM 54 placebo controlled 54 FTC TDF 54 Phase 1a 54 interferon lambda 54 Alocrest 54 Panzem 54 Ceftaroline 54 lamivudine zidovudine 54 EndoTAG TM -1 54 LEXIVA 54 imatinib resistant 54 RG# [001] 54 TELCYTA 54 catalytic antioxidant 54 masitinib 54 VQD 54 angiogenesis inhibitor 54 Ophena TM 54 immune modulatory 54 #I TM# 54 fusion protein 54 trabedersen 54 survivin 54 metastatic castration resistant 54 transcriptase inhibitor NNRTI 54 tgAAC# 54 selective inhibitors 54 cannabinor 54 PTP 1B 54 phase 2a 54 nucleoside analogs 54 placebo controlled Phase 54 Zysolin TM 54 Reolysin 54 MAb 54 Palifosfamide 54 Oritavancin 54 isotypes 54 fluoropyrimidine 54 Th1 type 54 immunological 54 P. aeruginosa 54 severe rotavirus gastroenteritis 54 Ceflatonin 54 Aplidin 54 Elitek 54 intermittent dosing 54 dose dependently 54 ZFN modified 54 HBV DNA 54 nilotinib 54 chronic lymphocytic leukemia CLL 54 HCV polymerase inhibitor 54 active metabolite 54 LymphoStat B belimumab 54 dose escalation Phase 54 PSMA ADC 54 liposomal amphotericin B 54 HBsAg 54 lead Aganocide compound 54 bosutinib 54 ataluren 54 cardiac toxicity 54 ROTARIX 54 induces antibodies 54 DU #b 54 PROMACTA 54 orally administered 54 L asparaginase 54 standard chemotherapy regimens 54 AMN# [001] 54 LB# [003] 54 BZL# 54 Anticalins 54 2 methoxyestradiol 54 sodium glucose cotransporter 54 small molecule inhibitors 54 interferon beta 54 CUDC 54 #D#C# 54 GAMMAGARD 54 lopinavir ritonavir 54 itraconazole Sporanox 54 lapatinib Tykerb 54 fluvastatin 54 PegIFN 54 fidaxomicin 54 miconazole 54 trastuzumab emtansine T DM1 54 TLR9 agonist 54 TNFa 54 xenografts 54 mouse xenograft models 54 efavirenz Sustiva 54 PegIFN RBV 54 lipid lowering therapies 54 Pharmacokinetic PK 54 viral loads 54 EZN 54 Dapagliflozin 54 heavily pretreated patients 54 Inhalation Solution 54 Civacir 54 ImmunoVEX HSV2 54 etoposide 54 dapsone 54 overexpressing 54 alpha 2b 54 ANAVEX #-# [001] 54 Pharmacokinetic analyzes 54 microRNA miR 54 Phase 2a clinical 54 Luteinizing Hormone Releasing Hormone 54 MUC1 54 hemagglutination inhibition 54 act synergistically 54 multiple ascending dose 54 custirsen 54 lixisenatide 54 HIV protease 54 TRAIL induced apoptosis 54 adipiplon 54 Akt activation 54 mAb 54 LEVADEX 54 HCD# [002] 54 platelet inhibitor 54 ORENCIA ® 54 genotype 1a 54 GAMMAGARD LIQUID 54 M2e 54 doxorubicin docetaxel

Back to home page